Loading
A phase 2 trial of Telotristat ethyl in Neuroendocrine tumours, run by Lowell Anthony, MD, recorded as terminated on the registry.
Telotristat With Lutathera in Neuroendocrine Tumors is a phase 2 interventional study registered as NCT04543955 by Lowell Anthony, MD, with 1 participants recorded, started 2021-09-13 and due to reach its primary completion in 2022-06-03. Interventions recorded: Telotristat (Low-Dose), Telotristat (High-Dose). Conditions recorded: Neuroendocrine Tumors.
Linked to the drug Telotristat ethyl because the registry names it among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.
Shares Telotristat ethyl and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.
Shares Neuroendocrine tumours and the tag pipeline.